Download PDF
Thromb Haemost 2004; 91(04): 837-838
DOI: 10.1055/s-0037-1614279
Letters to the Editor
Schattauer GmbH

PT G20210A and factor V Leiden mutations and isolated limb perfusion-associated thrombosis in patients with soft tissue sarcoma

Aydan Eroğlu
,
Arzu Ulu
,
Selim Erekul
,
Hikmet Akgul
,
Nejat Akar
Further Information

Publication History

Received 02 September 2003

Accepted after resubmission 23 December 2003

Publication Date:
08 December 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Creech O, Krementz ET, Ryan RF. et al. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958; 148: 616-32.
    CrossrefPubMedGoogle Scholar
  • 2 Eggermont AM, Koops HS, Klausner JM. et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicen-ter European experience. Ann Surg 1996; 224: 756-65.
    CrossrefPubMedGoogle Scholar
  • 3 Eroglu A, Kocaoglu H, Demirci S. et al. Isolated limb perfusion with cisplatin and doxorubicin for locally advanced soft issue sarcoma of an extremity. Eur J Surg Oncol 2000; 26: 213-21.
    CrossrefPubMedGoogle Scholar
  • 4 Klicks RJ, Vrouenraets BC, Nieweg OE. et al. Vascular complications of isolated limb perfusion. Eur J Surg Oncol 1998; 24: 288-91.
    CrossrefPubMedGoogle Scholar
  • 5 Eroğlu A, Özcan H, Eryavuz Y. et al. Deep venous thrombosis of the extremity diagnosed by color Doppler ultrasonography after isolated limb perfusion. Tumori 2001; 87: 187-90.
    PubMedGoogle Scholar
  • 6 Fraker DL, Coit DG. Isolated perfusion of extremity tumors. In: Regional therapy of advanced cancer. Lotze MT, Rubin JT. (Eds), 333-349 Lippincott-Raven; Philadelphia: 1997
    Google Scholar
  • 7 Dahlback B. Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood 1995; 85: 607-14.
    PubMedGoogle Scholar
  • 8 Bertina RM, Koeleman BP, Koster T. et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
    CrossrefPubMedGoogle Scholar
  • 9 Dahlback B. New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg 506 to Gin mutation in Factor V as pathogenic factor for venous thrombosis. Thromb Haemost 1995; 74: 139-48.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Poort SR, Rosendal FR, Reitsma PH. et al. common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
    PubMedGoogle Scholar
  • 11 Otterson GA, Monahan BP, Harold N. et al. Clinical significance of the FV:Q 506 mutation in unselected oncology patients. Am J Med 1996; 101: 406-12.
    CrossrefPubMedGoogle Scholar
  • 12 Sifontes MT, Nuss R, Hunger SP. et al. The factor V Leiden mutation in children with cancer and thrombosis. Br J Haematol 1997; 96: 484-9.
    CrossrefPubMedGoogle Scholar
  • 13 Haim N, Lanir N, Hoffman R. et al. Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism. Am J Med 2001; 110: 91-6.
    CrossrefPubMedGoogle Scholar
  • 14 Weitz IC, Israel VK, Liebman HA. Tamox-ifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden. Cancer 1997; 79: 2024-7.
    CrossrefPubMedGoogle Scholar
  • 15 Wriht DK, Manos MM. Sample preparation from paraffin-embedded tissues. In: PCR protocols. Innis MA, Gelfand DH, Sninsky JJ, White TJ. (Eds), Academic Press; San Diego: 153-8 1990
    Google Scholar